Respicardia Announces Highmark Coverage for the remedē® System in Patients with Central Sleep Apnea
Expanded insurance coverage now available in Pennsylvania, Delaware and West Virginia
TREATING
CENTRAL SLEEP APNEA
January 6, 2021
Expanded insurance coverage now available in Pennsylvania, Delaware and West Virginia
December 10, 2020
Respicardia, Inc. announced today that Monument Health in Rapid City, South Dakota is the first center in the Dakotas to treat patients with the remedē® System, an implantable device that uses phrenic nerve stimulation to treat central sleep apnea (CSA).
November 13, 2020
Respicardia, Inc. announced today that Novant Health Forsyth Medical Center in Winston-Salem, NC has treated its 25th patient with the remedē® System, an implantable device that treats central sleep apnea (CSA) by using phrenic nerve stimulation.
October 20, 2020
Trial results showed consistent improvement in sleep disordered breathing, arousals, sleep architecture, and daytime sleepiness through 5 years.
June 1, 2020
Respicardia, Inc. announced today that Richard L. Roudebush VA Medical Center in Indianapolis is the first center in Indiana to treat patients with the remedē® System, an implantable device that uses phrenic nerve stimulation to treat central sleep apnea (CSA).